Geurink Lars, van Tricht Ewoud, van der Burg Debbie, Scheppink Gerard, Pajic Bojana, Dudink Justin, Sänger-van de Griend Cari
Janssen Vaccines and Prevention B.V., CN Leiden, The Netherlands.
Department of Medicinal Chemistry, Faculty of Pharmacy, Biomedical Centre, Uppsala University, Uppsala, Sweden.
Electrophoresis. 2022 May;43(9-10):1068-1090. doi: 10.1002/elps.202100269. Epub 2021 Nov 21.
A broad range of CE applications from our organization is reviewed to give a flavor of the use of CE within the field of vaccine analyses. Applicability of CE for viral vaccine characterization, and release and stability testing of seasonal influenza virosomal vaccines, universal subunit influenza vaccines, Sabin inactivated polio vaccines (sIPV), and adenovirus vector vaccines were demonstrated. Diverse CZE, CE-SDS, CGE, and cIEF methods were developed, validated, and applied for virus, protein, posttranslational modifications, DNA, and excipient concentration determinations, as well as for the integrity and composition verifications, and identity testing (e.g., CZE for intact virus particles, CE-SDS application for hemagglutinin quantification and influenza strain identification, chloride or bromide determination in process samples). Results were supported by other methods such as RP-HPLC, dynamic light scattering (DLS), and zeta potential measurements. Overall, 16 CE methods are presented that were developed and applied, comprising six adenovirus methods, five viral protein methods, and methods for antibodies determination of glycans, host cell-DNA, excipient chloride, and process impurity bromide. These methods were applied to support in-process control, release, stability, process- and product characterization and development, and critical reagent testing. Thirteen methods were validated. Intact virus particles were analyzed at concentrations as low as 0.8 pmol/L. Overall, CE took viral vaccine testing beyond what was previously possible, improved process and product understanding, and, in total, safety, efficacy, and quality.
本文回顾了本组织广泛的毛细管电泳(CE)应用,以展现CE在疫苗分析领域的应用情况。结果表明,CE可用于病毒疫苗表征、季节性流感病毒体疫苗、通用亚单位流感疫苗、Sabin灭活脊髓灰质炎疫苗(sIPV)和腺病毒载体疫苗的放行及稳定性测试。开发、验证并应用了多种毛细管区带电泳(CZE)、毛细管电泳-十二烷基硫酸钠(CE-SDS)、毛细管凝胶电泳(CGE)和毛细管等电聚焦(cIEF)方法,用于病毒、蛋白质、翻译后修饰、DNA和辅料浓度的测定,以及完整性和组成验证及鉴别测试(例如,用CZE分析完整病毒颗粒,用CE-SDS定量血凝素和鉴定流感毒株,测定过程样品中的氯化物或溴化物)。结果得到了反相高效液相色谱(RP-HPLC)、动态光散射(DLS)和zeta电位测量等其他方法的支持。总体而言,本文介绍了16种已开发并应用的CE方法,包括6种腺病毒方法、5种病毒蛋白方法,以及用于测定聚糖、宿主细胞DNA、辅料氯化物和工艺杂质溴化物的抗体方法。这些方法用于支持过程控制、放行、稳定性、工艺和产品表征及开发,以及关键试剂测试。13种方法经过了验证。完整病毒颗粒的分析浓度低至0.8 pmol/L。总体而言,CE使病毒疫苗测试超越了以往的可能,增进了对工艺和产品的了解,进而提高了安全性、有效性和质量。